ProShares Ultra NASDAQ Biotechnology
30 hedge funds and large institutions have $14.8M invested in ProShares Ultra NASDAQ Biotechnology in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 8 closing their positions.
79% more call options, than puts
Call options by funds: $7.46M | Put options by funds: $4.16M
2.91% less ownership
Funds ownership: 10.46% → 7.55% (-2.9%)
12% less funds holding
Funds holding: 34 → 30 (-4)
41% less capital invested
Capital invested by funds: $25.3M → $14.8M (-$10.5M)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
50% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.91M |
| 2 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$1.67M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$636K |
| 4 |
Vontobel Holding
Zurich,
Switzerland
|
+$95.8K |
| 5 |
TCM
Traynor Capital Management
Malvern,
Pennsylvania
|
+$53.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFS
Sowell Financial Services
North Little Rock,
Arkansas
|
-$9.1M |
| 2 |
HF
HRT Financial
New York
|
-$2.01M |
| 3 |
CIC
Chase Investment Counsel
Charlottesville,
Virginia
|
-$1.28M |
| 4 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
-$1.07M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$637K |
BIB Hedge Fund Activity: Q1 2021 in Review
30 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q1 2021, worth a combined $14.8M — down 41% from $25.3M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of BIB and 4 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 5 added.
The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $1.91M. The largest seller was Sowell Financial Services, cutting an estimated $9.1M.
- 30 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q1 2021, down from 34 in Q4 2020.
- Funds reported $14.8M of ProShares Ultra NASDAQ Biotechnology stock for Q1 2021, down 41% quarter-over-quarter.
- 4 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q1 2021 and 8 closed out, a net change of -4 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q1 2021 was Tower Research Capital (TRC), an estimated $1.91M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q1 2021 was Sowell Financial Services, an estimated $9.1M sold.
Based on aggregated 13F filings for Q1 2021.